Novo Nordisk A/V (NYSE: NVO) stock is testing the patience of buy-and-hold investors. Over the last five years, NVO stock is up more than 200%. However, in the last year, it’s down over 61% and more than 43% in 2025. Even in the volatile medical stocks sector, that kind of underperformance can’t be overlooked.
But what’s making shareholders anxious right now is the company’s recent slash of full-year guidance, which caused the stock to drop by 3% in less than a week.
